Evidence map›Paper›PMID 30791119›Full record

ArticleHistopathology2019

Massively parallel sequencing analysis of benign melanocytic naevi.

John R Lozada, Felipe C Geyer, Pier Selenica, David Brown, Barbara Alemar, Taha Merghoub, Michael F Berger, Klaus J Busam, Allan C Halpern, Britta Weigelt and 2 more

Open access · greenAbstract read
In one paragraph

Article in Histopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

John R LozadaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Felipe C GeyerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID https://orcid.org/0000-0002-9978-6650
Pier SelenicaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David BrownDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Barbara AlemarDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Taha MerghoubDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael F BergerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Klaus J BusamDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Allan C HalpernDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID https://orcid.org/0000-0003-2969-3173
Travis J HollmannDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID https://orcid.org/0000-0003-1599-0433
Memorial Sloan Kettering Cancer Center · USUniversidade Federal do Rio Grande do Sul · BR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Breast Cancer Research FoundationNational Institutes of Health/National Cancer Institute P30CA008748NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

aimsMelanocytic naevi are benign lesions of the skin or mucosa that may constitute non-obligate precursors of malignant melanoma, particularly when they show lentiginous and dysplastic features. The aim of this study was to investigate the repertoire of somatic genetic alterations in melanocytic naevi. METHODS AND

resultsDNA extracted from 12 melanocytic naevi and DNA from matching normal tissue were separately microdissected and subjected to targeted massively parallel sequencing of ≥300 cancer genes. A median of 5.5 (range 1-12) non-synonymous somatic mutations were detected, with 10 cases harbouring mutually exclusive BRAF V600E (6/12) or NRAS (4/12) clonal hotspot mutations. One of the two cases lacking BRAF and NRAS mutations was a dysplastic naevus harbouring an HRAS Q61L hotspot mutation. Analysis of the laser-capture microdissected components of a naevus synchronously diagnosed with in-situ and invasive malignant melanoma revealed a truncal, clonal BRAF V600E mutation, and the acquisition of a CDKN2A homozygous deletion in the invasive component, in conjunction with additional clonal mutations affecting NF2, FAT4 and KDR in both in-situ and invasive malignant components.

conclusionMelanocytic naevi harbour recurrent BRAF V600E or NRAS hotspot mutations with low mutational burdens. Our findings also show that progression from naevi to malignant melanoma may be driven by the acquisition of additional genetic alterations, including CDKN2A homozygous deletions.

Indexed as

AdolescentAdultAgedCell Transformation, NeoplasticDNA Mutational AnalysisDNA, NeoplasmFemaleGTP PhosphohydrolasesHigh-Throughput Nucleotide SequencingHumansMaleMelanomaMembrane ProteinsMiddle AgedMutationNevus, PigmentedBRAF protein, humanDNA, NeoplasmGTP PhosphohydrolasesHRAS protein, humanMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)melanocytic naevimelanoma

Identifiers

PMID30791119
PMCPMC6752735
OpenAlexW2915122147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.